Literature DB >> 15854758

Retrograde dopaminergic neuron degeneration following intrastriatal proteasome inhibition.

Hideto Miwa1, Tomomi Kubo, Ai Suzuki, Katsunori Nishi, Tomoyoshi Kondo.   

Abstract

Recent studies have suggested that defects in the ubiquitin-proteasome system (UPS) contribute to the etiopathogenetic mechanisms underlying dopaminergic neuronal degeneration in Parkinson's disease. The present study aims to study the effects of proteasome inhibition in the nerve terminals of nigrostriatal dopaminergic neurons in the substantia nigra pars compacta (SNpc). Following a unilaterally intrastriatal injection of lactacystin, a selective proteasome inhibitor, dopaminergic neurons in the ipsilateral SNpc progressively degenerated with alpha-synuclein-immunopositive intracytoplasmic inclusions. When lactacystin was administered at a high concentration, the striatum was simultaneously involved, and alpha-synuclein-immunopositive extracytoplasmic granules appeared extensively within the SN pars reticulata (SNpr). In addition, during the retrograde neuron degeneration in SN, the level of heme oxygenase-1 immunopositivity, an oxidative stress marker, was markedly increased in SNpc neurons. These results reveal that intrastriatal proteasome inhibition sufficiently induces retrograde dopaminergic neuronal degeneration with abundant accumulation of alpha-synuclein in the SN.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15854758     DOI: 10.1016/j.neulet.2005.01.024

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  20 in total

Review 1.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

2.  Proteasome inhibitor does not enhance MPTP neurotoxicity in mice.

Authors:  Naoto Kadoguchi; Masahiro Umeda; Hiroyuki Kato; Tsutomu Araki
Journal:  Cell Mol Neurobiol       Date:  2008-03-14       Impact factor: 5.046

3.  Apigenin Reduces Proteasome Inhibition-Induced Neuronal Apoptosis by Suppressing the Cell Death Process.

Authors:  Arum Kim; Yoon Jeong Nam; Min Sung Lee; Yong Kyoo Shin; Dong Suep Sohn; Chung Soo Lee
Journal:  Neurochem Res       Date:  2016-07-29       Impact factor: 3.996

4.  Lamotrigine Attenuates Proteasome Inhibition-Induced Apoptosis by Suppressing the Activation of the Mitochondrial Pathway and the Caspase-8- and Bid-Dependent Pathways.

Authors:  Yoon Jeong Nam; Arum Kim; Min Sung Lee; Yong Kyoo Shin; Dong Suep Sohn; Chung Soo Lee
Journal:  Neurochem Res       Date:  2016-05-26       Impact factor: 3.996

5.  Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration.

Authors:  Brian N Mathur; M Diana Neely; Melanie Dyllick-Brenzinger; Anurag Tandon; Ariel Y Deutch
Journal:  Brain Res       Date:  2007-07-20       Impact factor: 3.252

6.  Failure of acute administration with proteasome inhibitor to provide a model of Parkinson's disease in mice.

Authors:  Naoto Kadoguchi; Hiroki Kimoto; Ryohei Yano; Hiroyuki Kato; Tsutomu Araki
Journal:  Metab Brain Dis       Date:  2008-04-19       Impact factor: 3.584

7.  Systemic administration of proteasome inhibitor protects against MPTP neurotoxicity in mice.

Authors:  Takuya Oshikawa; Hayato Kuroiwa; Ryohei Yano; Hironori Yokoyama; Naoto Kadoguchi; Hiroyuki Kato; Tsutomu Araki
Journal:  Cell Mol Neurobiol       Date:  2009-04-16       Impact factor: 5.046

8.  Adaptation to chronic MG132 reduces oxidative toxicity by a CuZnSOD-dependent mechanism.

Authors:  Rehana K Leak; Michael J Zigmond; Anthony K F Liou
Journal:  J Neurochem       Date:  2008-05-03       Impact factor: 5.372

9.  Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.

Authors:  Anthony C Vernon; Saga M Johansson; Michel M Modo
Journal:  BMC Neurosci       Date:  2010-01-05       Impact factor: 3.288

10.  Proteasome inhibitor-induced apoptosis is mediated by positive feedback amplification of PKCdelta proteolytic activation and mitochondrial translocation.

Authors:  Faneng Sun; Arthi Kanthasamy; Chunjuan Song; Yongjie Yang; Vellareddy Anantharam; Anumantha G Kanthasamy
Journal:  J Cell Mol Med       Date:  2008-02-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.